Trial Profile
Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 06 Sep 2018 Results published in the Vaccine
- 27 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 Dec 2006 New trial record.